Key facts
- OXOS’s last known valuation is $139.0M (Apr 2023).
- It has raised $56.7M; the latest was Later Stage VC ($10.7M) in Dec 2025.
- Notable investors include Sequoia Capital, MedTech Innovator, Intel Capital, Parkway Venture Capital, FedTech — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for OXOS
- ·The full record, as it builds
Funding rounds
No funding rounds for OXOS are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OXOS
Developer of a digital imaging device designed for efficient and effective treatment of patients. The company's devices are fluoroscopic instruments used to convert radiation to real-time static and dynamic fluoroscopic images of the human skeleton, as well as provide high-quality digital pictures and video of surgical anatomy and pathology, enabling surgeons, doctors and healthcare providers to bring the x-ray source to the target to produce more resolute images.
- Sector
- Healthcare
- HQ
- Atlanta, GA, United States
- Founded
- 2016
- Employees
- 70
- Website
- oxos.com/
- Ownership
- Privately Held (backing)
OXOS doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OXOS shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OXOS in its N-PORT filings yet. We sweep new filings monthly.